



1
 ACN 007 988 767
 Phone: +61 8 8234 2660
 Fax: +61 8 8234 6268
 Address: 8 Dalgicish Street
 Thebarton South Australia 5031
 www.bresagen.com

FACSIMILE TRANSMISSION

TO: The Office of International Corporate Finance
COMPANY: SEC
FAX NUMBER: 0011 1 202 772 9207
FROM: Trudy Fenton
DATE: Tuesday, 2 August 2005
SUBJECT: ASX Announcement
PAGES (inc. cover): 2

SUPPL

RECEIVED
 AUG 3 2005
 10:00 AM

In accordance with our obligation as a 12g3-2(b) filer, number 82-5135, to file home country announcements, please find the following announcement which was released by the Australian Stock Exchange today –

1. BresaGen signs Agreement with Peppen Corporation dated 2 August, 2005.

Yours sincerely

Trudy Fenton
 Corporate Administrator

PROCESSED
 AUG 04 2005
 THOMSON FINANCIAL

dw 8/3

If there are any problems with this transmission, call 08 8234 2660

This document and any following pages are intended solely for the named addressee, are confidential and may contain legally privileged information. The copying or distribution this information or any information this facsimile may contain by anyone other than the addressee, is prohibited. If you have received this document in error, please advise BresaGen by telephone and then return it by mail to the address above. We shall refund in full your costs in doing so.



ASX Release Tuesday 2 August, 2005

BresaGen signs Agreement with Pepgen Corporation

Adelaide biotechnology company, BresaGen Ltd has executed a contract with the US-based biopharmaceutical company, Pepgen Corporation (Alameda, CA) to progress the development of its auto-immune, inflammatory and viral therapies.

In 2004, BresaGen's protEcol™ Services business unit developed a process for Pepgen to produce a novel interferon alpha analog, Neoferon™.

Under the current contract BresaGen will further develop the *E. coli*-based process and produce GLP recombinant protein.

"We are pleased that Pepgen has chosen to continue working with BresaGen, as it validates the technology and capabilities of our protEcol™ Services business unit," commented BresaGen Managing Director, Dr Wolf Hanisch.

For further information contact:

Dr Meera Verma
Chief Operating Officer
BresaGen Limited
Phone: 08 8234 2660

About BresaGen Limited (BGN)

BresaGen is a biotechnology company focussed on cost-effective production of proteins and peptides in bacteria. The Company is located in Adelaide, South Australia and specialises in process development and supply of clinical trial material for third parties through its protEcol™ Services business unit. The Company focus is on supply of protein-based active pharmaceutical ingredients (API's) to pharmaceutical and biotechnology companies.
www.bresagen.com.au

About Pepgen Corporation

Pepgen Corporation, founded in 1992 by Dr. CP Liu is based in Alameda, CA. Pepgen is a privately held biopharmaceutical company seeking to develop and commercialize novel products for the prevention and treatment of autoimmune, inflammatory, and viral disorders.
www.pcpngen.com

Postal Address 8 Dalglish Street
PO Box 259 Thebarton SA 5031
Rundle Mall SA 5000 Australia www.bresagen.com.au

Telephone: +61 8 8234 2660
Facsimile +61 8 8234 6268
Email adelaide@bresagen.com.au

BresaGen Limited
ACN 007 988 767
ARN 60 007 988 767



ASX Release Monday 1 August, 2005

BresaGen Executes Contract for Process Development with Opsona Therapeutics

Adelaide biotechnology company, BresaGen Ltd has been contracted by Opsona Therapeutics Ltd based in Dublin, Republic of Ireland, to progress process development of its pre-clinical immunomodulator, OPN-201.

Over a 6 month period, BresaGen will conduct feasibility studies and process development for the eventual large-scale cGMP manufacture of recombinant OPN-201 in *E. coli* bacteria using BresaGen's protEcol™ Services technology and expertise.

Opsona is focussed on research and clinical development of drugs and vaccines for the treatment of auto-immune and inflammatory diseases.

For further information contact:

Dr Meera Verma
Chief Operating Officer
BresaGen Limited
Phone: 08 8234 2660

About BresaGen Limited (BGN)

BresaGen is a biotechnology company focussed on cost-effective production of proteins and peptides in bacteria. The Company is located in Adelaide, South Australia and specialises in process development and supply of clinical trial material for third parties through its protEcol™ Services business unit. The Company focus is on supply of protein-based active pharmaceutical ingredients (API's) to pharmaceutical and biotechnology companies.
www.bresagen.com.au

About Opsona Therapeutics Limited

Opsona is a drug discovery and development company, focused on novel therapeutic and preventative approaches for autoimmune and inflammatory diseases. Opsona's three scientific founders are world-renowned immunologists and Professors at Trinity College Dublin. Opsona is based in Dublin (Ireland).
www.opsona.com

Postal Address 8 Dalgleish Street
PO Box 259 Thebarton SA 5031
Rundle Mall SA 5000 Australia www.bresagen.com.au

Telephone +61 8 8234 2660
Facsimile +61 8 8234 6268
Email adelaide@bresagen.com.au

BresaGen Limited
ACN 007 988 767
ABN 60 007 988 767



1
ACN 007 988 767
Phone: +61 8 8234 2660
Fax: +61 8 8234 6268
Address: 8 Dalgleish Street
Thebarton South Australia 5031
www.bresagen.com

FACSIMILE TRANSMISSION

TO: The Office of International Corporate Finance
COMPANY: SEC
FAX NUMBER: 0011 1 202 772 9207
FROM: Trudy Fenton
DATE: Monday, 1 August 2005
SUBJECT: ASX Announcement
PAGES (inc. cover) 2

In accordance with our obligation as a 12g3-2(b) filer, number 82-5135, to file home country announcements, please find the following announcement which was released by the Australian Stock Exchange today –

1. BresaGen Executes Contract for Process Development with Opsona Therapeutics dated 1 August, 2005.

Yours sincerely

Trudy Fenton
Corporate Administrator

RECEIVED
12 AUG 2005 11:11 AM
COMMUNICATIONS

If there are any problems with this transmission, call 08 8234 2660

This document and any following pages are intended solely for the named addressee, are confidential and may contain legally privileged information. The copying or distribution this information or any information this facsimile may contain by anyone other than the addressee, is prohibited. If you have received this document in error, please advise BresaGen by telephone and then return it by mail to the address above. We shall refund in full your costs in doing so.